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Alzheimer’s disease (AD) and other diseases that cause de-
mentia are the greatest health and social care challenges of our
age [1]. Today, there are 50million people living with demen-
tia worldwide, and this is projected to increase to 135 million
by 2050 because of a rise in life expectancy and an aging pop-
ulation [2,3]. Current therapeutics for AD can transiently
improve cognitive symptoms in some patients, but they do
not treat the underlying causes of dementia or slow the rate
of disease progression [3,4]. Because the success rate for
the development of disease-modifying drugs for dementia dis-
eases has been disappointing, such as the failure of beta-
secretase 1 inhibitors to show efficacy, it is important to recon-
sider what the real barriers to progress in this field are and
identify emerging opportunities. It is intended that this anal-
ysis should inform the development of a strategic action
plan that will contribute to the G8 ambition of delivering a
disease-modifying treatment for dementia by 2025 and sup-
port progress toward and beyond this goal [3].2. Background
In December 2013, the UK government hosted the G8 de-
mentia summit to enable the members of the constituent coun-
tries to discuss and formulate an international approach to the
global challenge of dementia [5]. The G8 stated that dementia
research should be made a global priority with a key aim of
developing a cure or disease-modifying therapy by 2025
[3,5]. During the Summit, it was also agreed that dementia
researchwas underresourced and underfunded [5]; this has sub-
sequently led to the establishment of a number of important
research initiatives aimed at addressing this specific challenge
[6–10]. For example in the UK, in 2015, the UK Government
published the “Challenge on Dementia 2020”, an iteration of
the 2012 Dementia Challenge, outlining the government’s
aims to improve dementia care, support, and research by
2020 [6]. To meet this challenge, in the UK, the Medical
ResearchCouncil (MRC), part ofUKResearch and Innovation,
founded the Dementias Platform UK (DPUK) [7] in 2014 with
£50 million support for coordinated data and clinical research
infrastructures and experimental medicine collaborations with
industry. The Dementia Discovery Fund [8] was established
in 2015 as a global venture capital fund with the aim of invest-ing in new and emerging disease-modifying therapeutic ap-
proaches and facilitating the progression of potential new
drug targets through early clinical development and testing.
In addition, in 2015, the Drug Discovery Alliance (DDA) [9]
was launched by the Alzheimer’s Research UK (ARUK),
bringing together three institutes (University of Cambridge,
University of Oxford, and University College London) with
the aim of bridging the gap between discovery science and
drug development. In addition, the UK Dementia Research
Institute (UK DRI) [10] was founded in 2016, comprising six
centers within universities across the UK, with £290 million
of cofunding from the MRC, the ARUK, and the Alzheimer’s
Society. Together, the DDA, DPUK, and UKDRI aim to trans-
form the treatment, care, prevention, and diagnosis of demen-
tia, through coordinated discovery science and translation to
people living with dementia.
Despite these and other efforts, significant gaps still exist
that hamper the development of disease-modifying treat-
ments for dementias. To address these gaps, the ARUK
convened a panel of experts in the dementia field, including
global academic and industry researchers, to identify and
prioritize key thematic areas that are not the current focus
of research and funding initiatives in this field. During 15
and 16 May 2018, the panel met in London, UK, to discuss
how to tackle each specific gap and develop an action plan
around each theme. The action plan was intended to be a
vision for the future, to provide important information to
facilitate the progress of dementia research and ultimately
inform and direct the development of life-changing treat-
ments for dementia.
The meeting was organized around six themes: (1) trans-
lating genetic risk factors into biological processes; (2)
better understanding neuronal resilience to inform novel
drug targets; (3) facilitating robust and reproducible drug-
target validation; (4) identifying appropriate populations of
appropriate subjects for phase IIa proof-of-concept clinical
trials; (5) improving approaches to assess drug-target
engagement in humans; and (6) innovative approaches to
conducting clinical trials if we are able to detect dementia
diseases 10–15 years earlier than we are able to today.
Each theme will be reviewed in this paper, and the key rec-
ommendations are outlined. We also include a preliminary
action plan as an attempt to begin to address and resolve
these recommendations.
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processes
3.1. Understanding genetic vulnerability and its impact on
neuronal health and biology
Important advances have been made in identifying ge-
netic factors that contribute to the risk of developing diseases
that may cause dementia, and particularly AD. Mutations in
amyloid precursor protein and presenilin 1 and 2 cause auto-
somal dominant AD, and the apolipoprotein E (APO E) ε4
allele is a major risk factor for late-onset AD [11]. A key
goal of current AD research is to seek out novel disease-
risk genes, elucidate their biological function in the develop-
ment of the disease, and try to interpret important gene-gene
or gene-environment interactions with the aim of identifying
novel approaches to the treatment and prevention of AD and
other neurodegenerative diseases. The standard method for
identifying disease-risk genes has been genome-wide asso-
ciation studies (GWAS), and this approach has led to the
identification of (at least) additional 21 genetic risk loci
[12]. However, these are highly complex diseases likely
caused by the composite action of multiple disease-related
genes. This compounds the challenge of translating genetic
findings into functional mechanisms that are important in
disease pathogenesis [12] and consequently, valid targets
for the development of effective therapeutics. Discussions
in this session focused on approaches to improve the trans-
lation of genetic findings into disease biology using a
more integrated biology approach, better tools, and analysis
of genotype-phenotype correlations to provide a more
comprehensive understanding of disease causation and
inform future therapeutic drug discovery and biomarkers.
As many genetic factors have been identified as contrib-
uting to the risk for developing AD, the research focus has
shifted from identifying novel risk factors toward under-
standing how such risk factors lead to changes in biological
processes and pathways, some of which are already known
to be affected in dementing and other neurodegenerative dis-
eases. Moving from genetic data to a potential therapeutics
will involve different tools and areas of expertise, including
in silico and laboratory approaches to structural biology, cell
biology, and pharmacology. Leveraging emerging technolo-
gies (such as single cell studies or induced pluripotent stem
cell models) will also enable acceleration of the investiga-
tion of the links between genetic data and potential therapeu-
tics. The Open Targets partnership is a good example of this
approach [13]. It brings together expertise from six different
institutions and uses human genetics and genomics data to
systematically identify and prioritize drug targets for thera-
peutic development [13]. Another good example is seen in
schizophrenia research, where understanding the role of
the complement component 4 locus involved the application
of different tools and datasets (including GWAS and expres-
sion data from postmortem brains), and genetic engineering
of animal models to understand the biological mechanism[14]. This approach identified potential biological targets
from genetic data that may result in the development of
novel therapeutics. These examples of partnerships and col-
laborations, and application of different tools, should be
more widely adopted by the dementia research community
to bridge the gap between genetic signals to biologically
relevant therapeutic targets. Interdisciplinarity and develop-
ment/application of a broad range of tools and technologies
are also at the heart of the UK DRI research network, aiming
to accelerate our mechanistic understanding of dementia to
find newways to prevent, diagnose, and treat dementia effec-
tively [10].
A significant challenge in translating genetic data into
biological processes is the lack of understanding of the un-
derlying role of individual genes and how they relate to dis-
ease progression and phenotype in later life. Genomic
analysis across the natural history of the disease would
enable a better understanding of the genes involved at
different stages of disease, provide additional insight into
the disease mechanism(s), and inform the development of
alternative interventions or new areas of research. Part of
this genetic analysis should also include identification of
the genetic influences on rate of disease progression. This
could be approached by capitalizing on longitudinally phe-
notyped cohorts that include and contrast subjects with spo-
radic AD to analyze the genotype-phenotype interactions
and progression of the disease.
To support these approaches, it will be important to iden-
tify key expertise from different disciplines that are currently
missing from dementia research and proactively engagewith
subject matter experts from diverse areas such as data sci-
ence, not only to bring that expertise into the dementia field
but also to promote the exchange of knowledge and innova-
tion. Barriers to collaborative and interdisciplinary research
also need to be understood and addressed. For example, in-
trainstitutional collaborations may have been hindered in the
UK by the fact that a publication could only be submitted
once to the former Research Excellence Framework assess-
ments from each institution [15]. The evaluation of collabo-
rative research outputs has changed, with a greater emphasis
on impact and contribution, but further changes in the eval-
uation and recognition process are needed if we are to foster
true collaborative efforts.
There is also a need to bring together experts from other
relevant disease and basic science areas of expertise, partic-
ularly those shown to have an increasingly important role in
dementia research (e.g., immunologists and lipid biologists)
and to encourage intradisciplinary and interdisciplinary
collaboration. This approach has been successful in Hun-
tington’s disease research, where the CHDI Foundation
(https://chdifoundation.org/) manages a network of more
than 600 researchers worldwide, facilitating the sharing of
ideas and information that encourages active collaboration.
A similar model could be adopted for dementia research.
Dementia symposia and workshop sessions could be
included in conferences hosted by other disciplines, such
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experts in relevant fields could chair these symposia or work-
shops (e.g., asking immunologists to lead neuroinflamma-
tion discussions). Such approaches would encourage
crossdiscipline fertilization and potentially bring new exper-
tise into the dementia field.
This approach has been adopted by the DPUK for exper-
imental medicine working groups and the Wellcome Trust
Consortium for the Neuroimmunology of Mood Disorders
and Alzheimer’s Disease (NIMA) [16]. The NIMA Con-
sortium is investigating novel therapeutic and biomarker ap-
proaches for neurodegeneration based on the biological links
between inflammation and neurodegeneration and a number
of clinical compounds derived from immunology drug dis-
covery. To address this challenge, the Consortium assembled
a team of academic and industry scientists with diverse
expertise in imaging, animal models, clinical phenotyping,
and informatics. Such collaborative and interdisciplinary ap-
proaches could facilitate the translation of genetic research
that impacts on cell biology into neurodegenerative research
and development.
3.2. Summary of recommendations and suggested actions
1. Facilitate translation of genetic risk factors into target-
able biological processes and pathways using a more
integrated biology approach.
2. Support the application of tools and expertise from
other fields to better translate genetic information
into cell biology and drug development.
3. Encourage research that seeks to carry out genomic
analysis along disease progression to identify the
genes involved at different stages of disease.
4. Support interdisciplinary collaboration and the devel-
opment of dementia symposia and workshop sessions
in other relevant disciplines to foster cross-
fertilization of ideas and bring new expertise into the
dementia field.4. Better understanding selective neuronal vulnerability
and resilience to inform novel drug targets
4.1. Could a better understanding of why some neurons
die and others are resistant to cell death identify novel drug
targets?
This session was focused on why some neuronal cell pop-
ulations die very early in the course of the disease, others die
at a later stage, and still others do not seem to degenerate at
all, and whether understanding this difference could help
identify novel targets for drug development. Recent research
has identified multiple neurodegenerative pathways that
result in a domino-like cascade of events that eventually
lead to the development of dementias. However, these
changes are not seen in all cases of AD [17,18].The characteristic features of AD are the pathological
accumulation of extracellular plaques composed of
amyloid-b (Ab) protein and intraneuronal tangles
consisting of altered forms of tau [17]. A long-standing puz-
zle in AD research has been the finding that there may be a
substantial number of Ab plaques in the brain of some indi-
viduals who have otherwise normal cognition and
conversely people who exhibit phenotypic AD have little
or no plaque or tangle deposition [19,20]. Studies show
that Ab deposition is an early event that may play a
harmful role in the development of AD; however, the
mechanisms that link Ab to neurodegeneration are poorly
understood. Moreover, intermediate Ab species (e.g.,
oligomers) perhaps contribute more to nerve injury than to
plaques [21]. Clinically relevant symptoms tend to emerge
around the same time as tau pathology is correlated with
cell death, although it is also acknowledged that the interme-
diate oligomeric species may play a critical role in such
developments [22]. Moreover, some brain regions (hippo-
campus, amygdala, and cerebral cortex) appear to show a
selective vulnerability to plaque accumulation and tau-
associated neurodegeneration, while others (basal ganglia,
cerebellum, brain stem, and spinal cord) are initially spared
[23,24].
These observations suggest that understanding why some
brain structures are more vulnerable to insults than others
could be gained by examining the molecular differences be-
tween neurons that are susceptible to neurodegeneration and
those that are relatively protected. For example, excitatory
but not inhibitory neurons, which differ in their expression
of proteins that enable protein degradation, accumulate
damaging tau aggregates in a genetically engineered mouse
model of tau pathology spread [25]. This type of approach
may aid the identification of novel disease mechanisms
that could be exploited to develop alternative therapeutic tar-
gets for disease management with a potentially higher suc-
cess rate for treatment. For example, recent studies have
explored the locus coeruleus, a brainstem nucleus in the cen-
tral nervous system (CNS) that is the primary site for produc-
tion of noradrenaline and has diffuse noradrenergic
innervation. Noradrenergic neurons in this region play a cen-
tral role in normal cognitive function, and so, loss of inner-
vation in this region is postulated to be linked to a cognitive
decline, suggesting that noradrenaline signaling in the CNS
might be a viable therapeutic target [26].
The key advance enabling this approach was the possibil-
ity of biologically mapping the molecular signature of
different neuronal populations in healthy brains versus
brains from subjects with neurodegenerative diseases. This
may lead to a better understanding of the biological pro-
cesses associated with neuronal vulnerability and may allow
for a spatial and chronological characterization of the neural
cell systems affected in dementia. The Allen Institute is
making progress in this area, with a project entitled Aging,
Dementia and Traumatic Brain Injury Study [27] within
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and expand the potential of these projects by integrating
data from different research groups globally. This requires
overcoming barriers to data sharing, data accessibility, and
integrative approaches across institutions to enable intercon-
nection/interoperability and linkage of datasets. A comple-
mentary approach to mapping neuronal vulnerability has
also been suggested at the National Institute of Health AD
Summit 2018 [29] to develop an AD connectivity map based
on “omics” expression signatures in disease-relevant cell
types. Further investigation using an omics-based approach
could systematically map resilience and vulnerability by
brain region and tracking the trajectory of the disease [30].
Integrating multiple sets of omics data using computational
and statistical tools can be used to analyze the molecular
pathways in specific brain regions and perhaps identify the
more vulnerable pathways. Others have suggested that addi-
tional approaches are needed, such as a more active investi-
gation of glia and vascular changes [31].
This could be studied using longitudinal structural mag-
netic resonance imaging (MRI) or synapse positron-
emission tomography (PET) imaging; however, another
important aspect is the evaluation of postmortem or resected
human tissue, something that is not necessarily straightfor-
ward to obtain from well-characterized cases and without
significant postmortem delay, required for high-quality sam-
ples. It was proposed that researchers need better access to
living tissue from people living with dementia, and the panel
recommended that this be achieved by enabling access to re-
sected tissue from surgeries and using excess biopsy tissue.
One approach suggested to streamline access was through
the UK Brain Banks Network, a coordinated national
network of UK brain tissue resources for research purposes
[32]. It would be important for neurosurgeons to follow a
standard operating procedure (SOP) to facilitate the collec-
tion of high-quality tissue for the brain banks, and so, it
was proposed to develop SOPs in collaboration with the
MRC Brain Bank Initiative and to identify the best practice
globally. It was also suggested that the Brain Bank Steering
Committee engage with cohort principal investigators to
encourage them to obtain consent for the use of brain tissue
for research purposes. Other suggestions included encour-
aging preconsenting for people living with dementia in clin-
ical trials for postmortem brain donation, collaborating more
closely with neurosurgeons, and standardizing brain tissue
processing to maintain its usefulness for study (e.g., rapid
cooling of excised brain tissue).
Finally, dementia research organizations can set the
agenda, drive research, and encourage collaboration by
sharing of information with the wider research community
[33]. Preclinical biological data can often be difficult to
disseminate in an accessible format because of the unstruc-
tured nature of certain data sets, for example, omics-type
data and imaging. Developing solutions for data sharing
and accessibility may enable the field to progress at a
faster rate.4.2. Summary of recommendations and suggested actions
1. Use an omics-based approach and others such as im-
aging to map resilience and vulnerability by brain re-
gion including all cell types to better understand
disease processes, characterize disease trajectory,
and potentially yield novel targets for drug discovery.
2. Access to tissue
i. Generate neurosurgical SOPs to enable research ac-
cess to excess biopsy tissue and resected tissue from
neurosurgery, when undertaken for clinical indica-
tions.
ii. Encourage preconsenting for those in trials for
postmortem brain donation and ensure procedures
are in place to optimize this process (e.g. enforce
procedures to ensure rapid brain cooling at time
of death).5. Robust and reproducible target validation
5.1. The need to improve validation of potential drug
targets
Currently, only symptomatic treatments for dementia are
available. At best, they transiently provide limited cognitive
benefit in approximately 40% of people living with demen-
tia, and they have no impact on the underlying disease pro-
cesses or the rate of cognitive decline [3,4]. While
development of symptomatic treatments has slowed, the
search for dementia-preventing or dementia-modifying
treatments has increased significantly [34].
A plethora of innovative approaches to drug discovery are
emerging, with the identification of putative novel mecha-
nisms and potential drug targets being published in high pro-
file journals. However, robust and reproducible biological
validation of potential new molecular targets is key to suc-
cessful and productive drug discovery. It is critical that
exciting early published findings can be reproduced across
different model systems and laboratories to provide confi-
dence when moving from laboratory to clinic. However,
translating these early novel biology findings into robust
drug-target validation is often met with failure, and there
are still many significant barriers to successful drug develop-
ment. The reasons for this are many fold, including incen-
tives to publish preclinical work without the necessary
robust evidence for relevance of applicability to human dis-
ease; fundamental differences in the biology and degenera-
tion of brain cells in different species; and limitations in
the human disease models and outcomes. Incentives to pub-
lish novel findings as rapidly as possible detracts from repro-
ducing initial novel findings either within the same academic
lab or in independent labs. Grant funding does not always
readily allow the reproduction of findings in different
in vitro and in vivo models, and validation data are less
attractive to publishers. In addition, the pressure on both ac-
ademic and biotech researchers to progress targets rapidly
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port robustness or establishing cross-species homologies.
While these issues are not confined to dementia research,
the current paradigm for target validation in neurodegenera-
tive research should be strengthened significantly with an
emphasis on both robustness and reproducibility of early
preclinical experimental methodology and findings.
Significant effort is required to address these issues with
emphasis on training and awareness (e.g., scientists trained
in pharmacology and rigorous experimental design
including robust statistics). High-quality collaborative and
interdisciplinary proposals should be incentivized to
encourage research groups working on identical/similar tar-
gets can share their expertize, minimize risk and cost, and
improve robustness and reproducibility through integration
of diverse disciplines. There was also consensus that incen-
tivizing validation of potential drug targets through cross
verification from two or more sources, for example bioinfor-
matics data, genetics, cell biology in vitro and in vivo, and
real-world observational data, would result in significant
long-term benefits.
The results of an interesting discussion on facilitating
reproducibility and robustness of early experimental find-
ings focused on the expertise of independent grant review.
It was proposed that high-quality grant review could be
achieved by the following: (1) encouraging wider expertise
from other fields to participate in the grant peer-review pro-
cess; (2) provide detailed and constructive feedback, which
can help researchers better understand how to achieve robust
target validation; and (3) use of good practice guidelines that
can be shared across the scientific community. Examples of
good practice methodology could be collated to develop the
guidelines for drug-target validation similar to the Animal
Research: Reporting In Vivo Experiments–the (ARRIVE)
guidelines [35] or the Organization for Human Brain Map-
ping’s Committee on Best Practice in Data Analysis and
Sharing [36].
Incentives to researchers have not always supported
robustness and reproducibility of data, where tenure and pro-
motion structures have placed great emphasis on novel,
high-impact research, which may have high impact, but risks
nonreproducible outputs based on a limited number of ex-
periments. Therefore, the incentive structure and training
should be reconfigured to also promote validation of results.
It is important to raise awareness and incentivize drug-target
validation and translation as a critical process of drug devel-
opment, for example, encouraging researchers to conduct
experiments that provide predefined “NoGo” decision end-
points in a research proposal, effectively rewarding the
termination of futile lines of enquiry. These proposals could
be adopted readily and included in the guidelines for grant
applications and could be an additional criterion for review.
Wider dissemination of information on ineffective tech-
nologies/techniques and publishing of negative results
should also be supported. This could be achieved through
funders encouraging open research platforms (e.g., AMRCOpen Research https://amrcopenresearch.org/, Wellcome
Trust Open Research https://wellcome.ac.uk/what-we-do/
our-work/open-research, and Alzforum https://www.
alzforum.org/) to publish data that might otherwise not be
published by peer-reviewed journals (e.g., negative data).
This would enable more timely “Go”/”NoGo” decisions to
be made and streamline the translational pipeline.
The drug-target validation process is at the interface be-
tween academia and industry, and promoting better collabo-
ration between the two can lead to a better understanding of
the basic science of AD and the requirements for drug devel-
opment. This will ultimately improve and enhance the vali-
dation of novel biological findings. Progress in this area has
been made through initiatives such as the ARUK’s Drug Dis-
covery Alliance and Dementia Consortium [37] and the US
initiative Accelerating Medicines Partnership - Alzheimer’s
Disease (AMP-AD) [38], although a lot needs to be done to
expand this and other collaboration models to additional in-
stitutions and countries.
The translation of laboratory-based findings to clinically
relevant therapies is very complex. Preclinical testing of po-
tential new therapies for AD and other neurodegenerative
disorders relies on effective animal models of disease or dis-
ease mechanisms that have both face and construct validity.
While all animal models have their limitations, a number of
established and accepted pharmacodynamic animal models,
based on familial mutations in AD, are now used widely to
support dementia research. However, even with these select
number of models, there is extensive variability in the design
of animal experiments between different research groups.
This results in animal models with varying characteristics,
which ultimately leads to lack of consistent validation. Com-
pounding the issue is the lab variability introduced by not us-
ing the appropriate background or control strains. To
improve validation, optimized experimental design proto-
cols for animal models in dementia should be developed
and standardized. This should entail an in-depth review of
existing models and experimental procedures followed by
open publication of standardized animal protocols and pro-
motion of their use (e.g., preference setting by high profile
journals and funding bodies), similar to the NEWMEDS
initiative for schizophrenia research [39]. Scientists working
in osteoarthritis research have recently published “consider-
ations for the design and execution of protocols for animal
research and treatment” [40] to complement the ARRIVE
guidelines [35], and a guide has also been produced for Hun-
tington’s disease animal models [41]. A similar protocol
could be developed and adopted for animal model research
in dementia diseases.5.2. Summary of recommendations and suggested actions
1. Provide training for scientists in areas of skill gaps
(e.g. pharmacology and statistics) and facilitate
collaboration.
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cross verification with different sources of data and
different experimental systems.
i. Funders should require robust validation ap-
proaches in funding applications, with use of multi-
ple data sources/systems and, where appropriate,
use of independent labs.
3. Support the sharing of information on ineffective tech-
nologies/techniques and publishing of negative re-
sults.
i. Funders should encourage open research platforms
(such as Alzforum) to publish negative data and the
scenarios within which they are tested.
4. Facilitate translation from novel target validation to
early drug discovery (e.g. through models such as
the ARUK Dementia Consortium, where expert scien-
tists from different sectors work together).
5. Develop an optimized experimental design protocol
for animal model research.
i. Review experimental design and methodologies
and publicize and encourage use of suggested stan-
dardized protocols.6. Appropriate choice of subject populations for proof-
of-concept clinical trials
6.1. Whom to select for early proof-of-concept clinical
trials
Between 2002 and 2012, only one compound of 244 eval-
uated in clinical trials for AD reached the market, translating
to an overall attrition rate of 99.6%, with 98% of those eval-
uated in phase III clinical trials failing to show efficacy [42].
The number of compounds that progress to regulatory re-
view is among the lowest for any therapeutic area [42].
One of the factors often linked to this high failure rate is
inappropriate selection of subject populations in early clin-
ical trials, leading to results that fail to translate through to
phase III trials. A key aim of phase Ib/IIa studies is to
show proof of pharmacology over a short period of time,
and these trials typically restrict inclusion to a very small
fraction of the total pool of people living with dementia
(e.g., excluding by common comorbidities or narrow stage
of disease). Thus, the typical phase IIa population of people
living with dementia may not be representative of the wider
cohort that is the likely population to be evaluated in phase
III. For AD, it may be beneficial to consider using a more
heterogeneous population in phase IIb trials, to increase
the probability of success in the wider patient populations
or to restrict recruitment in phase III trials to a population
of patients more likely to benefit from a particular treatment.
The current challenge of recruiting appropriate subjects
to proof-of-concept clinical trials is complex, given the
questions that need to be addressed by early stage studies,
that is, safety and proof of mechanism/efficacy on disease
progression within a relatively short period of time. Forevaluation of an AD, therapeutic prodromal AD and/or
early AD may not be the relevant populations, as the time
taken to show a clear change in cognitive decline is likely
to be beyond the reasonable duration of such trials (typically
over 18 months), until a time when there is a consensus on
more sensitive endpoints. Therefore, to effectively demon-
strate proof of concept, alternative subject populations
could be recruited to these studies, with subsequent studies
expanding to include the AD populations. This strategy re-
lies on the true relevance or functional equivalence of the
alternative population to AD. Such equivalence is often
assumed but rarely proven. For example, targeting clearly
defined populations such as Down syndrome or familial
AD to demonstrate mechanistic efficacy could not only
facilitate therapeutic proof of concept but also enable the
development of treatments for populations with significant
unmet medical need. If proof of concept were to be demon-
strated in these groups, trials could then be expanded to
incorporate the wider AD population. In both the Down syn-
drome and familial AD populations, Ab and tau pathology
plus the onset of cognitive impairment follows a path
similar to that in sporadic AD, but in both populations,
the onset and progression of the disease is more predictable
and homogeneous with less comorbidity than late onset
populations [43,44].
The aims for research and development in recruiting peo-
ple with Down syndrome, familial AD, and sporadic AD to a
study somewhat differ. People with Down syndrome repre-
sent a population to explore the early efficacy of drugs,
particularly those targeted against Ab and tau, which slow
down disease progression. Almost all people with Down
syndrome progress to AD and dementia, with an Ab pathol-
ogy which is very similar to that observed in people with AD
[43]. Thus, they represent a population of huge unmet med-
ical need in their own right. In addition, they arguably repre-
sent a more homogeneous population where the Ab
pathology is well defined and where drugs can be evaluated
for pharmacodynamic effects and early efficacy at a very
early stage in the disease process. The latter is also arguably
the case for familial AD. However, one important consider-
ation is that both these populations are different to the major-
ity of people with sporadic or late-onset AD: they are
younger, more commonly present with phenotypes other
than typical amnestic mild cognitive impairment AD and
have subtly different neuropathology to sporadic AD and
differences in the role of vascular pathology in pathogenesis.
In addition, in peoplewith Down syndrome, the variability in
premorbid cognitive function raises challenges for outcome
measures and informed consent issues, which is not the case
in familial AD. These and other differences may compro-
mise the predictability of a drug effect, given the nonequiv-
alence to most people with AD. Even taking this into
account, these populations may offer a route to deliver early
proof of efficacy for some compounds and should be consid-
ered on a case-by-case basis depending on the mechanism of
treatment.
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explored to better stratify subjects into clinical trials. There
is a requirement to identify, recruit, characterize, and allo-
cate people using clinical study registers to create dementia
cohorts. One potential solution is using longitudinal pheno-
typed clinical registries and readiness cohorts, the current
strategy of the DPUK (which includes the Deep and
Frequent Phenotyping study) and European Prevention of
Alzheimer’s Dementia (EPAD) Consortium respectively
[45,46]. Furthermore, there is currently very little
information on genetic factors linked to the rate of disease
progression or phenotypic variance (e.g., amnestic vs.
posterior cortical atrophy vs. logopenic aphasia variants of
AD). Large scale and long-term registers allow for people
to be profiled mechanistically and longitudinally, including
disease progression, to distinguish genetic and environ-
mental determinants of fast versus slow progressors,
enabling more accurate stratification for clinical trials.
This approach has been informative in Parkinson’s disease
and frontotemporal dementia [47,48].
Recruitment of individuals to clinical trials remains low
even with the existence of many cohorts and the aforemen-
tioned registries. To improve recruitment to clinical trials, it
is important to understand the barriers and incentives to in-
crease clinical trial participation and to engage with prin-
cipal investigators to incentivize the use of cohorts. This
is one of the priority areas promoted by Bill Gates in his
plans for investment in AD [49]. One barrier to increasing
clinical trial participation by well-characterized subjects
within existing cohorts is the mutual exclusivity between
longitudinal observational phenotyping for several years
and therapeutic studies; these activities do not need to be
mutually exclusive, but in practice, they often are. To
address this issue, it is essential that participation in
research is increased so that both types of studies can
coexist without mutual exclusion.
6.2. Summary of recommendations and suggested actions
1. Select relevant populations which best address the
questions being asked at the relevant stage of develop
ment that is, proof of concept/mechanism/pharma
cology.ii. Focus on mechanism/pharmacology/efficacy in
clearly defined populations initially to allow demon
stration of proof of mechanism/pharmacology and
subsequently expand to the wider AD population
if appropriate.
ii. Examples of such populations could be Down syn
drome or familial AD, where there are huge unmet
medical needs, and pathology is sufficiently similar
to that of sporadic AD, but disease progression is
more rapid or more predictable.
ii. Early proof-of-concept populations could provide
the predictive data required to expedite the next
phases of clinical development.2. Consider how to improve genotype-phenotype transla-
tion to enable stratification of people living with de-
mentia for clinical trials.
i. A longitudinally phenotyped experimental medicine
register could facilitate this.
ii. Profile people living with dementia mechanistically
and longitudinally along disease progression to bet
ter understand the biology/pathology associated
with fast and slow progressors to enable accurate
stratification.
3. Understand barriers and incentives to increasing clin
ical trial participation and incentivize the use of co
horts and registries.
i. Longitudinal observational phenotyped cohorts and
therapeutic readiness cohorts are often mutually
exclusive but are equally critical for clinical
research–increase participation in research to fill
both cohorts.
7. Improving approaches to assess drug-target
engagement in humans
7.1. Making more informed decisions in clinical
development
Before neurodegenerative disease therapeutics entering
the clinical pipeline, they are screened for their pharma-
cology, pharmacodynamics, pharmacokinetics, and toxicity
in preclinical model systems. Data from these studies are in-
tended to inform factors such as safety, optimal clinical dose
range, blood-brain barrier penetration, and binding to the in-
tended target [50]. Although these preclinical data are infor-
mative, they do not fully describe all the clinical findings in
early human trials. It is therefore important to be able to
makemore informed “Go”/“NoGo”decisions early in clinical
development and establish approaches to minimize risk and
maximize the potential for success as a therapy progresses
through the various stages of clinical development [50].
Demonstrating proof of target engagement/pharma-
cology in humans early in clinical development is crucial
for reducing the risk involved in progressing novel drug ther-
apeutics from phase I safety/pharmacokinetic studies to later
stage efficacy studies. In other fields, such as psychiatry, as-
certaining the clinical pharmacology profile of novel drugs
in early clinical development is a relatively common practice
(e.g., PET ligand displacement studies) but is often over-
looked in neurology therapeutics development, often due
to lack of appropriate tools in clinical practice. Instead, com-
pounds are progressed directly from phase I/Ib safety/toler-
ability studies into phase IIb/III efficacy studies. This
strategy, particularly used in the narrow focus of the devel-
opment of therapeutic antibodies, can contribute to poor de-
cision making along the path of dementia drug development
and testing, leading to unsatisfactory outcomes in costly, late
stage clinical trials.
If achievable, being able to show drug-target engagement
and pharmacological consequence at the site of action
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therapeutics reaches and engages the relevant target site of
action; (2) it determines the relevant pharmacological dose
range for moving to later stage clinical trials; (3) it signifi-
cantly reduces the risk of progressing a drug inappropriately
into a late stage development; (4) it allows optimization of
dosing regimen based on established pharmacokinetic/phar-
macodynamic relationships; and (5) it provides confidence
that the mechanistic hypothesis, being targeted by the thera-
peutics, is truly being evaluated for efficacy in a population
of people living with dementia. However, owing to the costs
associated with this early stage of development (particularly
if new tools/approaches are needed) and a need for more
rapid therapeutic development, there may be the potential
to bypass these studies. Thus, it is important to find more
collaborative risk- and cost-sharing approaches to show
target engagement and drug pharmacology as these studies
are critical in early drug development. To date, disease-
modifying drugs that have reached phase III clinical trials
are primarily either small molecules or immunotherapies
that target Ab [34]. Behind this wave of Ab targeted drugs
are those that are directed toward tau [34] including those
which reduce tau hyperphosphorylation, tau accumulation
or prevent the spread of toxic tau species. The current meth-
odologies that demonstrate target engagement for tau are
limited to cerebrospinal fluid (CSF) biomarker measure-
ments because of current uncertainty over off-target binding
of PET ligands, even if heuristical binding of these ligands
highly correlates with disease pathology and phenotype
[51]. More recently, there has been a focus on targeting
various neuroinflammation pathways and processes. It is
important, therefore, to establish methodologies for
measuring target engagement or proof of pharmacology
across a range of these drug-target classes, to facilitate a
risk-reduced progression of such drugs to the next stage of
development.
A second area that is gathering momentum is the mea-
surement of synaptic integrity and health; this can poten-
tially provide a pharmacodynamic endpoint for many
different therapeutic approaches and also has the poten-
tial to serve as a relevant diagnostic biomarker. Relevant
methodologies include PET approaches for measuring
synaptic density and magnetoencephalography to mea-
sure circuit function including changes in oscillations
[52]. One example of such an approach is the synaptic
vesicle glycoprotein 2A (SV2A) PET ligand (radioligand)
[53] (UCB-J) which is currently being evaluated as means
of quantifying synaptic density. This radioligand has been
validated in humans including people with AD [53].
Initial studies suggest this approach may not only provide
evidence of target engagement and early proof of mecha-
nistic concept but also could provide an approach to
assess prognostic drug efficacy and potentially being use-
ful as a diagnostic for neurodegenerative diseases more
generally.The discussions in this session focused on how to scope
and facilitate collaboration in developing cost- and risk-
sharing approaches to demonstrate target engagement,
drug pharmacology, and pharmacodynamic effects for target
class mechanisms, for example, tau or neuroinflammation.
This would span different drug approaches across multiple
companies/partners. A potential approach is to establish
public-private partnerships, similar to the DPUK’s Synaptic
Health Theme, and themodel used by the ARUK’s Dementia
Consortium for early drug discovery projects [7,37]. The
Consortium aims, through a cost- and risk-sharing approach,
to translate fundamental academic research to early drug dis-
covery programmes for new dementia treatment [37].
Regarding the exploration of new methodologies for
measuring target engagement and proof of pharmacology,
one area that is underdeveloped in the UK is the sampling
of CSF for relevant pharmacological endpoints. CSF is a
useful resource in AD, given the breadth of analysis now
available, for determining drug pharmacodynamic effects,
pharmacology, and target engagement as well as assessment
of disease biomarkers, tracking disease progression, and
potentially improving early diagnosis [54]. However, unlike
some other European countries, lumbar punctures are less
commonly used in dementia clinical practice and dementia
research. CSF sampling has recently been included in the up-
dated National Institute of Care Excellence dementia guide-
lines, also showing the importance of this resource in a
clinical setting [55]. Potential solutions to this issue would
be to raise awareness of the high tolerability and utility of
lumbar puncture, within both healthcare providers and the
general public. However, it was noted that to achieve success
in this area in the UK, it is necessary to understand how to
change the culture and training for CSF collections to
become a routine procedure.
The UK is a major partner in the international develop-
ment of other new technologies for dementia research,
including multiple UK center participation in the EU Joint
Program–Neurodegenerative Disease Research (JPND)
2016-17 initiative for standardization and harmonization of
new methods including magnetoencephalography, tau-
PET, and ultrahigh fieldMRI [56]. UK and international sup-
port for these initiatives has succeeded in bringing expertize
into dementia research which had not been previously
engaged.7.2. Summary of recommendations and suggested actions
1. To scope and facilitate collaboration in developing
cost- and risk-sharing approaches to demonstrate
target engagement, proof of mechanism, and proof
of drug pharmacology for drug mechanisms common
across multiple companies/partners.
i. Public-private partnership approach, similar to the
cost-sharing, risk-sharing approach set-up for the
ARUK’s Dementia Consortium and DPUK.
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currently in late stage preclinical development.
2. Facilitate the use of CSF sampling to determine target
engagement, proof of drug mechanism, and effects on
pharmacodynamic endpoints.
i. Understand how to change the culture, improve
training, and encourage CSF collections to become
a routine procedure.
3. Support advances in translating putative pharmacody-
namic endpoints into useful clinical assays.8. Innovative approaches to conduct clinical trials if we
are able to detect diseases 10–15 years earlier than we do
today
8.1. How to approach clinical trials differently if
detection/diagnosis is achieved earlier
The majority of potential AD therapeutics have failed to
show efficacy in phase III clinical trials. At the time of
writing, there have been no new drug approvals for treating
AD since 2003. A potential reason for lack of efficacious and
novel therapeutics in late stage clinical trials is that treatment
intervention may be occurring at too late a stage in the dis-
ease process. There is a widespread agreement among ex-
perts that if we were able to detect, and ultimately
diagnose, disease at a much earlier stage then the chance
of successful disease-modification, in addition to symptom-
atic therapies, would increase significantly. To this end, re-
searchers are looking toward developing tools that will
allow early detection, diagnosis, and treatment of diseases
underpinning dementia at an early stage of disease. As a
minimum, these tools could help to efficiently and accu-
rately triage at-risk individuals for detailed clinical diag-
nosis, but ideally, they would provide a tool that detects
and subsequently diagnoses early stage disease, where
perturbation of the disease process itself pharmacologically
would have the greatest long-term therapeutic benefit.
Several hurdles need to be overcome if such detection/
diagnostic tools do become available, not least that the dura-
tion of phase IIb/III clinical trials will increase significantly
to allow measurement of clinical efficacy of drugs. Already,
with the disease-modifying drugs currently in development,
it is a challenge to conduct trials of sufficient duration to
demonstrate a difference in the slope of cognitive decline.
Early detection/diagnosis will compound this issue if exist-
ing cognitive outcomes retain primacy as measures of a
beneficial effect, as trials will be required to run for even
longer periods. If we are able to reliably detect/diagnose
10–15 years earlier, innovative approaches to how late stage
clinical trials are conducted and implemented will be neces-
sary which may include novel cognitive outcome measures
more sensitive to neurodegenerative changes at their earliest
phase [57]. Regulatory bodies are looking to provide condi-
tional approval of dementia drugs based on surrogate
markers which may enable alternative means of collectingphase III clinical trial data in a “real-world” setting utilizing
memory and brain health clinics for data collection [58].
This would allow for passive and active monitoring remotely
using standard clinical endpoints but also digital approaches,
generating “real-world” data. To address this, a community-
based trial protocol is currently being developed by the
ARUK to provide an exemplar of conducting real world
(e.g., memory clinic-based) pivotal clinical trials for AD
(“virtual” clinical trial). To achieve this, there needs to be
an increased engagement with regulators to inform guideline
development, and regulators need to be persuaded of the
value of a virtual clinical trial approach.
An alternative and complimentary strategy is to develop
more sensitive tools for detecting cognitive change that can
be used at-scale. Many outcome measures use well-
established technologies that have been developed for use
specifically in a clinical context. These measures are unsuit-
able for use in large preclinical populations. A strong case
can be made for a new generation of digital cognitive pheno-
typing tools that can detect early changes indicating increased
clinical risk. This is an opportunity for stakeholders to collab-
orate in developing standard tools that are understood and
accepted by regulators, industry, and academia.
If it is possible to detect AD much earlier than current
methods allow, an important factor to consider is the impact
for individuals who have the disease detected and their fam-
ilies. Current trials use different outcome measures (clinical,
functional, and biological) to determine the efficacy of the
treatment; however, these outcomes have not determined pa-
tients and their careers but are instead an objectivemeasure of
clinical symptoms. Therefore, it will be extremely important
to understand the preferred outcomes of people living with
dementia for early stages of disease, which can then inform
drug development and provide additional endpoints for clin-
ical trials. To this aim, the ARUK has begun to explore an
outcome project in collaboration with researchers, people
affected by dementia, clinicians, and regulators [59]. It is
important to continue supporting projects to understand the
outcomes people living with dementia prefer and persuade
both the research community and regulators of the impor-
tance of these in informing clinical trial design and conduct.
The AD community is not alone in facing these issues. The
EU JPND supported a cross-disciplinary working group,
the Presymptomatic Neurodegeneration Initiative, where re-
searchers, funders, and regulators considered analogous
challenges in AD, frontotemporal dementia, motor neuron
disease, Huntington’s disease, and other conditions [60].
Conducting longer clinical trials will also have implica-
tions for data protection regulation. Innovators have patent
protection and data exclusivity for several years. However,
with treatments shifting to earlier stages of the disease and
the possibility that patients may not survive for many years
after drug approval because of longer clinical trials, there
may be a need to evolve data protection regulation and
patient life in line with developments in approaches to
treatment.
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1. If we detect neurodegenerative diseases 10-15 years
earlier, propose and theoretically validate a new
approach for conducting and implementing late-
stage, pivotal clinical trials.
i. Develop a community-based trial protocol to pro-
vide an exemplar of conducting a real world (e.g.
memory clinic) pivotal clinical trial for AD.
ii. Engage with regulators and relevant bodies to
inform the development of an innovative approach
to the conduct of late stage clinical trials including
digital cognitive phenotyping strategies.
iii. Educate regulators regarding the value of a “vir-
tual” clinical trial approach.
2. Understand outcomes people living with dementia
prefer for early stages of disease, which can inform
drug development and provide additional endpoints
for clinical trials.
3. Work with relevant stakeholders to evolve data protec-
tion regulations in line with the shift to treating earlier
in the disease course.9. Conclusions
The national and global objective of delivering a disease-
modifying treatment for dementia by 2025, as well as the
development of improved symptomatic therapies, will
require a multifaceted approach to broaden current research
areas by addressing prevention, earlier detection/diagnosis,
disease mechanisms, and the design of clinical trials. Spe-
cific recommendations and actions detailed in this paper
include
 Using a more integrated biology approach to translate
genetic data into cell biology.
 Map resilience and vulnerability by brain region using
an “omics”-based approach.
 Include requirements in funding applications for robust
target validation in preclinical models and humans.
 Using multiple data sources to increase reliability and
reproducibility of findings.
 Focus on demonstrating proof of mechanism/pharma-
cology/efficacy in clearly defined populations (e.g.,
Down syndrome) initially and subsequently expanding
to the wider AD population.
 Develop cost- and risk-sharing approaches to demon-
strate target engagement.
 Developing a community-based clinical trial protocol
to promote a paradigm shift in how late stage clinical
trials could be conducted.
In addition to specific recommendations for individual
themes, there were also a number of recommendations that
were relevant across all the themes. These include incentiv-
izing collaborations both within the dementia field and withother fields, consideration of data sharing, interoperability
and centralized databases, promoting and supporting the
sharing of research tools, changing the incentives in
academia and industry to encourage a more collaborative
approach, and raising education and awareness of the public,
research community, and clinicians. The overarching resolu-
tion is to find additional ways to incentivize collaboration,
particularly interdisciplinary collaboration, to standardize
approaches, to rethink clinical approaches to early and late
stage clinical trials, and to efficiently and comprehensively
share data and samples at all levels across the scientific com-
munity. All are essential to accelerate the progress toward the
goal of developing an effective treatment for AD by 2025.Acknowledgments
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1. Systematic review: The authors reviewed the litera-
ture on dementia research from PubMed and other
sources, and consulted with key opinion leaders in
the field to determine the areas of dementia research
not currently being addressed by existing initiatives.
These gaps were discussed at a meeting where lead-
ing experts in the field of neurodegeneration research
developed recommendations and action plans to
address them.
2. Interpretation: Recommendations and action plans
were developed to address the following: (1) transla-
tion of genetic risk factors into biological processes;
(2) improve understanding of selective neuronal re-
silience to guide drug development; (3) enabling
robust and reproducible target validation; (4) appro-
priate selection of people living with dementia for
proof-of-concept clinical trials; (5) improving drug-
target engagement in humans; and (6) innovative
approaches to conduct clinical trials.
3. Future directions: To accelerate progress in dementia
research, it is essential to incentivize collaboration,
especially interdisciplinary collaboration, to increase
the reproducibility of research findings, to develop
innovative approaches to clinical trial design, and
to efficiently and comprehensively share data and in-
formation across the scientific community. Clear ac-
tion plans are being developed and agreed to address
these issues.
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